NCT03658967View on ClinicalTrials.gov

Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 7, 2018

Primary Completion Date

December 16, 2019

Study Completion Date

October 23, 2024

Conditions
Secondary Lymphedema
Interventions
DRUG

Lymfactin® (1x10E11 vp)

Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.

DRUG

Placebo

Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.

Trial Locations (5)

Unknown

Töölö Hospital, Department of Plastic Surgery, Helsinki

Tampere University Hospital, Department of Plastic Surgery, Tampere

Turku University Hospital, Department of Plastic Surgery, Turku

Karolinska University Hospital, Department of Reconstructive Plastic Surgery, Stockholm

Uppsala University Hospital, Department of Plastic Surgery, Uppsala

Sponsors
All Listed Sponsors
lead

Herantis Pharma Plc.

INDUSTRY

NCT03658967 - Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE) | Biotech Hunter | Biotech Hunter